1
|
Zhang YL, Moran SP, Allen A, Baez-Nieto D, Xu Q, Wang LA, Martenis WE, Sacher JR, Gale JP, Weïwer M, Wagner FF, Pan JQ. Novel Fluorescence-Based High-Throughput FLIPR Assay Utilizing Membrane-Tethered Genetic Calcium Sensors to Identify T-Type Calcium Channel Modulators. ACS Pharmacol Transl Sci 2022; 5:156-168. [PMID: 35311021 PMCID: PMC8923061 DOI: 10.1021/acsptsci.1c00233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Indexed: 11/28/2022]
Abstract
T-type voltage-gated Ca2+ channels have been implicated in many human disorders, and there has been increasing interest in developing highly selective and potent T-type Ca2+ channel modulators for potential clinical use. However, the unique biophysical properties of T-type Ca2+ channels are not conducive for developing high-throughput screening (HTS) assays to identify modulators, particularly potentiators. To illustrate, T-type Ca2+ channels are largely inactivated and unable to open to allow Ca2+ influx at -25 mV, the typical resting membrane potential of the cell lines commonly used in cellular screening assays. To address this issue, we developed cell lines that express Kir2.3 channels to hyperpolarize the membrane potential to -70 mV, thus allowing T-type channels to return to their resting state where they can be subsequently activated by membrane depolarization in the presence of extracellular KCl. Furthermore, to simplify the HTS assay and to reduce reagent cost, we stably expressed a membrane-tethered genetic calcium sensor, GCaMP6s-CAAX, that displays superior signal to the background compared to the untethered GCaMP6s or the synthetic Ca2+ sensor Fluo-4AM. Here, we describe a novel GCaMP6s-CAAX-based calcium assay utilizing a high-throughput fluorometric imaging plate reader (Molecular Devices, Sunnyvale, CA) format that can identify both activators and inhibitors of T-type Ca2+ channels. Lastly, we demonstrate the utility of this novel fluorescence-based assay to evaluate the activities of two distinct G-protein-coupled receptors, thus expanding the use of GCaMP6s-CAAX to a wide range of applications relevant for developing cellular assays in drug discovery.
Collapse
|
2
|
Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med 2019. [PMID: 29515000 DOI: 10.1126/scitranslmed.aam8460] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Glycogen synthase kinase 3 (GSK3), a key regulatory kinase in the wingless-type MMTV integration site family (WNT) pathway, is a therapeutic target of interest in many diseases. Although dual GSK3α/β inhibitors have entered clinical trials, none has successfully translated to clinical application. Mechanism-based toxicities, driven in part by the inhibition of both GSK3 paralogs and subsequent β-catenin stabilization, are a concern in the translation of this target class because mutations and overexpression of β-catenin are associated with many cancers. Knockdown of GSK3α or GSK3β individually does not increase β-catenin and offers a conceptual resolution to targeting GSK3: paralog-selective inhibition. However, inadequate chemical tools exist. The design of selective adenosine triphosphate (ATP)-competitive inhibitors poses a drug discovery challenge due to the high homology (95% identity and 100% similarity) in this binding domain. Taking advantage of an Asp133→Glu196 "switch" in their kinase hinge, we present a rational design strategy toward the discovery of paralog-selective GSK3 inhibitors. These GSK3α- and GSK3β-selective inhibitors provide insights into GSK3 targeting in acute myeloid leukemia (AML), where GSK3α was identified as a therapeutic target using genetic approaches. The GSK3α-selective compound BRD0705 inhibits kinase function and does not stabilize β-catenin, mitigating potential neoplastic concerns. BRD0705 induces myeloid differentiation and impairs colony formation in AML cells, with no apparent effect on normal hematopoietic cells. Moreover, BRD0705 impairs leukemia initiation and prolongs survival in AML mouse models. These studies demonstrate feasibility of paralog-selective GSK3α inhibition, offering a promising therapeutic approach in AML.
Collapse
Affiliation(s)
- Florence F Wagner
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
| | - Lina Benajiba
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.,INSERM U1163 and CNRS 8254, Imagine Institute, Université Paris Saclay, 91190 Paris, France
| | - Arthur J Campbell
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Michel Weïwer
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Joshua R Sacher
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Jennifer P Gale
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Linda Ross
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Alexandre Puissant
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.,INSERM U944, Institute of Hematology, St. Louis Hospital, 75010 Paris, France
| | - Gabriela Alexe
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.,Bioinformatics Graduate Program, Boston University, Boston, MA 02215, USA
| | - Amy Conway
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Morgan Back
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Yana Pikman
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Ilene Galinsky
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Daniel J DeAngelo
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Richard M Stone
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Taner Kaya
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Xi Shi
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Matthew B Robers
- Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
| | - Thomas Machleidt
- Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
| | | | - Olivier Hermine
- INSERM U1163 and CNRS 8254, Imagine Institute, Université Sorbonne Paris Cité, Paris, France.,Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, 75006 Paris, France
| | - Andrew Kung
- Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | | | | | - Michael T Hemann
- Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Edward Scolnick
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Yan-Ling Zhang
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Jen Q Pan
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Kimberly Stegmaier
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA. .,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.,Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Edward B Holson
- Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| |
Collapse
|
3
|
Weïwer M, Xu Q, Gale JP, Lewis M, Campbell AJ, Schroeder FA, Van de Bittner GC, Walk M, Amaya A, Su P, D Ordevic L, Sacher JR, Skepner A, Fei D, Dennehy K, Nguyen S, Faloon PW, Perez J, Cottrell JR, Liu F, Palmer M, Pan JQ, Hooker JM, Zhang YL, Scolnick E, Wagner FF, Holson EB. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment. ACS Chem Biol 2018; 13:1038-1047. [PMID: 29485852 DOI: 10.1021/acschembio.8b00168] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Schizophrenia is a severe neuropsychiatric disease that lacks completely effective and safe therapies. As a polygenic disorder, genetic studies have only started to shed light on its complex etiology. To date, the positive symptoms of schizophrenia are well-managed by antipsychotic drugs, which primarily target the dopamine D2 receptor (D2R). However, these antipsychotics are often accompanied by severe side effects, including motoric symptoms. At D2R, antipsychotic drugs antagonize both G-protein dependent (Gαi/o) signaling and G-protein independent (β-arrestin) signaling. However, the relevant contributions of the distinct D2R signaling pathways to antipsychotic efficacy and on-target side effects (motoric) are still incompletely understood. Recent evidence from mouse genetic and pharmacological studies point to β-arrestin signaling as the major driver of antipsychotic efficacy and suggest that a β-arrestin biased D2R antagonist could achieve an additional level of selectivity at D2R, increasing the therapeutic index of next generation antipsychotics. Here, we characterize BRD5814, a highly brain penetrant β-arrestin biased D2R antagonist. BRD5814 demonstrated good target engagement via PET imaging, achieving efficacy in an amphetamine-induced hyperlocomotion mouse model with strongly reduced motoric side effects in a rotarod performance test. This proof of concept study opens the possibility for the development of a new generation of pathway selective antipsychotics at D2R with reduced side effect profiles for the treatment of schizophrenia.
Collapse
Affiliation(s)
- Michel Weïwer
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Qihong Xu
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Jennifer P Gale
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Michael Lewis
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Arthur J Campbell
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Frederick A Schroeder
- Department of Radiology, MGH , Athinoula A. Martinos Center for Biomedical Imaging , Charlestown , Massachusetts 02129 , United States
| | - Genevieve C Van de Bittner
- Department of Radiology, MGH , Athinoula A. Martinos Center for Biomedical Imaging , Charlestown , Massachusetts 02129 , United States
| | - Michelle Walk
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Aldo Amaya
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Ping Su
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , University of Toronto , Toronto , Ontario M5T1R8 , Canada
| | - Luka D Ordevic
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Joshua R Sacher
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Adam Skepner
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - David Fei
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Kelly Dennehy
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Shannon Nguyen
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Patrick W Faloon
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Jose Perez
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Jeffrey R Cottrell
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Fang Liu
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , University of Toronto , Toronto , Ontario M5T1R8 , Canada
| | - Michelle Palmer
- Center for the Development of Therapeutics , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Jen Q Pan
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Jacob M Hooker
- Department of Radiology, MGH , Athinoula A. Martinos Center for Biomedical Imaging , Charlestown , Massachusetts 02129 , United States
| | - Yan-Ling Zhang
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Edward Scolnick
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Florence F Wagner
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| | - Edward B Holson
- Stanley Center for Psychiatric Research , Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States
| |
Collapse
|
4
|
Wagner FF, Bishop JA, Gale JP, Shi X, Walk M, Ketterman J, Patnaik D, Barker D, Walpita D, Campbell AJ, Nguyen S, Lewis M, Ross L, Weïwer M, An WF, Germain AR, Nag PP, Metkar S, Kaya T, Dandapani S, Olson DE, Barbe AL, Lazzaro F, Sacher JR, Cheah JH, Fei D, Perez J, Munoz B, Palmer M, Stegmaier K, Schreiber SL, Scolnick E, Zhang YL, Haggarty SJ, Holson EB, Pan JQ. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol 2016; 11:1952-63. [PMID: 27128528 DOI: 10.1021/acschembio.6b00306] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphorylation. GSK3 comprises two highly similar paralogs, GSK3α and GSK3β, which are key regulatory kinases in the canonical Wnt pathway. GSK3 stands as a nodal target within this pathway and is an attractive therapeutic target for multiple indications. Despite being an active field of research for the past 20 years, many GSK3 inhibitors demonstrate either poor to moderate selectivity versus the broader human kinome or physicochemical properties unsuitable for use in in vitro systems or in vivo models. A nonconventional analysis of data from a GSK3β inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. Taking advantage of an uncommon tridentate interaction with the hinge region of GSK3, we developed highly selective and potent GSK3 inhibitors, BRD1652 and BRD0209, which demonstrated in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. These new chemical probes open the way for exclusive analyses of the function of GSK3 kinases in multiple signaling pathways involved in many prevalent disorders.
Collapse
Affiliation(s)
| | - Joshua A. Bishop
- Chemical Neurobiology Laboratory, Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02215, United States
| | | | | | | | | | - Debasis Patnaik
- Chemical Neurobiology Laboratory, Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02215, United States
| | | | | | | | | | | | - Linda Ross
- Department
of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, Massachusetts 02215, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Kimberly Stegmaier
- Department
of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, Massachusetts 02215, United States
| | | | | | | | - Stephen J. Haggarty
- Chemical Neurobiology Laboratory, Departments of Neurology & Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02215, United States
| | | | | |
Collapse
|
5
|
Wagner FF, Zhang YL, Fass DM, Joseph N, Gale JP, Weïwer M, McCarren P, Fisher SL, Kaya T, Zhao WN, Reis SA, Hennig KM, Thomas M, Lemercier BC, Lewis MC, Guan JS, Moyer MP, Scolnick E, Haggarty SJ, Tsai LH, Holson EB. Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chem Sci 2015; 6:804-815. [PMID: 25642316 PMCID: PMC4310013 DOI: 10.1039/c4sc02130d] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Kinetically selective inhibitors of HDAC2 enhanced learning and memory in a CK-p25 mouse model of neurodegeneration.
Aiming towards the development of novel nootropic therapeutics to address the cognitive impairment common to a range of brain disorders, we set out to develop highly selective small molecule inhibitors of HDAC2, a chromatin modifying histone deacetylase implicated in memory formation and synaptic plasticity. Novel ortho-aminoanilide inhibitors were designed and evaluated for their ability to selectively inhibit HDAC2 versus the other Class I HDACs. Kinetic and thermodynamic binding properties were essential elements of our design strategy and two novel classes of ortho-aminoanilides, that exhibit kinetic selectivity (biased residence time) for HDAC2 versus the highly homologous isoform HDAC1, were identified. These kinetically selective HDAC2 inhibitors (BRD6688 and BRD4884) increased H4K12 and H3K9 histone acetylation in primary mouse neuronal cell culture assays, in the hippocampus of CK-p25 mice, a model of neurodegenerative disease, and rescued the associated memory deficits of these mice in a cognition behavioural model. These studies demonstrate for the first time that selective pharmacological inhibition of HDAC2 is feasible and that inhibition of the catalytic activity of this enzyme may serve as a therapeutic approach towards enhancing the learning and memory processes that are affected in many neurological and psychiatric disorders.
Collapse
Affiliation(s)
- F F Wagner
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - Y-L Zhang
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - D M Fass
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; SL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts, USA
| | - N Joseph
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - J P Gale
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - M Weïwer
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - P McCarren
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - S L Fisher
- SL Fisher Consulting, LLC, PO Box 3052, Framingham, Massachusetts, USA
| | - T Kaya
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - W-N Zhao
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - S A Reis
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - K M Hennig
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - M Thomas
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - B C Lemercier
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - M C Lewis
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - J S Guan
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - M P Moyer
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - E Scolnick
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| | - S J Haggarty
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Chemical Neurobiology Laboratory, Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology and Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | - L-H Tsai
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA ; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Howard Hughes Medical Institute, Cambridge, Massachusetts, USA
| | - E B Holson
- Stanley Center for Psychiatric Research; Broad Institute of Harvard and MIT; 7 Cambridge Center, Cambridge, Massachusetts, USA
| |
Collapse
|
6
|
Olson DE, Wagner FF, Kaya T, Gale JP, Aidoud N, Davoine EL, Lazzaro F, Weïwer M, Zhang YL, Holson EB. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem 2013; 56:4816-20. [PMID: 23672185 DOI: 10.1021/jm400390r] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
We disclose the first small molecule histone deacetylase (HDAC) inhibitor (3, BRD73954) capable of potently and selectively inhibiting both HDAC6 and HDAC8 despite the fact that these isoforms belong to distinct phylogenetic classes within the HDAC family of enzymes. Our data demonstrate that meta substituents of phenyl hydroxamic acids are readily accommodated upon binding to HDAC6 and, furthermore, are necessary for the potent inhibition of HDAC8.
Collapse
Affiliation(s)
- David E Olson
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Wagner FF, Olson DE, Gale JP, Kaya T, Weïwer M, Aidoud N, Thomas M, Davoine EL, Lemercier BC, Zhang YL, Holson EB. Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif. J Med Chem 2013; 56:1772-6. [DOI: 10.1021/jm301355j] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Florence F. Wagner
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - David E. Olson
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Jennifer P. Gale
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Taner Kaya
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Michel Weïwer
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Nadia Aidoud
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Méryl Thomas
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Emeline L. Davoine
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Bérénice C. Lemercier
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Yan-Ling Zhang
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| | - Edward B. Holson
- Stanley Center for Psychiatric Research, Broad Institute
of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142,
United States
| |
Collapse
|
8
|
Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Palmer M, Scherer CA, Stern AM, Schreiber SL, Munoz B. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett 2012; 3:1034-1038. [PMID: 23256033 PMCID: PMC3523537 DOI: 10.1021/ml300246r] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Accepted: 10/22/2012] [Indexed: 12/31/2022] Open
Abstract
![]()
The KRAS oncogene is found in up to 30% of all human
tumors. In
2009, RNAi experiments revealed that lowering mRNA levels of a transcript
encoding the serine/threonine kinase STK33 was selectively toxic to
KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors
of STK33 might selectively target KRAS-dependent cancers. To test
this hypothesis, we initiated a high-throughput screen using compounds
in the Molecular Libraries Small Molecule Repository (MLSMR). Several
hits were identified, and one of these, a quinoxalinone derivative,
was optimized. Extensive SAR studies were performed and led to the
chemical probe ML281 that showed low nanomolar inhibition of purified
recombinant STK33 and a distinct selectivity profile as compared to
other STK33 inhibitors that were reported in the course of these studies.
Even at the highest concentration tested (10 μM), ML281 had
no effect on the viability of KRAS-dependent cancer cells. These results
are consistent with other recent reports using small-molecule STK33
inhibitors. Small molecules having different chemical structures and
kinase-selectivity profiles are needed to fully understand the role
of STK33 in KRAS-dependent cancers. In this regard, ML281 is a valuable
addition to small-molecule probes of STK33.
Collapse
Affiliation(s)
- Michel Weïwer
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - James Spoonamore
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Jingqiang Wei
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Boris Guichard
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Nathan T. Ross
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Kristina Masson
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Whitney Silkworth
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Sivaraman Dandapani
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Michelle Palmer
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Christina A. Scherer
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Andrew M. Stern
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Stuart L. Schreiber
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Howard Hughes Medical Institute, Department of Chemistry & Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Benito Munoz
- Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
9
|
Dockendorff C, Nagiec MM, Weïwer M, Buhrlage S, Ting A, Nag PP, Germain A, Kim HJ, Youngsaye W, Scherer C, Bennion M, Xue L, Stanton BZ, Lewis TA, MacPherson L, Palmer M, Foley MA, Perez JR, Schreiber SL. Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies. ACS Med Chem Lett 2012; 3:808-813. [PMID: 23074541 PMCID: PMC3469069 DOI: 10.1021/ml300172p] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 08/18/2012] [Indexed: 12/16/2022] Open
Abstract
![]()
Macrocyclic Hedgehog (Hh) pathway inhibitors have been
discovered
with improved potency and maximal inhibition relative to the previously
reported macrocycle robotnikinin. Analogues were prepared using a
modular and efficient build-couple-pair (BCP) approach, with a ring-closing
metathesis step to form the macrocyclic ring. Varying the position
of the macrocycle nitrogen and oxygen atoms provided inhibitors with
improved activity in cellular assays; the most potent analogue was 29 (BRD-6851), with an IC50 of 0.4 μM against
C3H10T1/2 cells undergoing Hh-induced activation, as measured by Gli1 transcription and alkaline phosphatase induction. Studies
with Patched knockout (Ptch–/–) cells and competition studies with the Smoothened (Smo) agonists
SAG and purmorphamine demonstrate that in contrast to robotnikinin,
select analogues are Smo antagonists.
Collapse
Affiliation(s)
- Chris Dockendorff
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Marek M. Nagiec
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Michel Weïwer
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Sara Buhrlage
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Amal Ting
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Partha P. Nag
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Andrew Germain
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Han-Je Kim
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Willmen Youngsaye
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Christina Scherer
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Melissa Bennion
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Linlong Xue
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Benjamin Z. Stanton
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Timothy A. Lewis
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Lawrence MacPherson
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Michelle Palmer
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Michael A. Foley
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - José R. Perez
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Stuart L. Schreiber
- Chemical
Biology Platform and Probe Development Center and ‡Howard Hughes Medical Institute, Broad Institute of Harvard and MIT,
7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
10
|
Heidebrecht RW, Mulrooney C, Austin CP, Barker RH, Beaudoin JA, Cheng KCC, Comer E, Dandapani S, Dick J, Duvall JR, Ekland EH, Fidock DA, Fitzgerald M, Foley M, Guha R, Hinkson P, Kramer M, Lukens AK, Masi D, Marcaurelle L, Su XZ, Thomas CJ, Weïwer M, Wiegand RC, Wirth D, Xia M, Yuan J, Zhao J, Palmer M, Munoz B, Schreiber S. Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Med Chem Lett 2012; 3:112-117. [PMID: 22328964 PMCID: PMC3276110 DOI: 10.1021/ml200244k] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Accepted: 12/14/2011] [Indexed: 02/06/2023] Open
Abstract
Here, we describe the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites. Screening a novel compound collection created using diversity-oriented synthesis (DOS) led to the initial hit. Structure-activity relationships guided the synthesis of compounds having improved potency and water solubility, yielding a subnanomolar inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma. This compound is available via the molecular libraries probe production centers network (MLPCN) and is designated ML238.
Collapse
Affiliation(s)
- Richard W. Heidebrecht
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Harvard School of Public Health, Huntington Avenue,
Boston, Massachusetts 02115, United States
| | - Carol Mulrooney
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Christopher P. Austin
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Robert H. Barker
- Genzyme Corporation, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Jennifer A. Beaudoin
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Ken Chih-Chien Cheng
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Eamon Comer
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Sivaraman Dandapani
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Justin Dick
- Harvard School of Public Health, Huntington Avenue,
Boston, Massachusetts 02115, United States
| | - Jeremy R. Duvall
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Eric H. Ekland
- Department of Microbiology and Immunology, Colombia University, New York, New York 10032, United
States
| | - David A. Fidock
- Department of Microbiology and Immunology, Colombia University, New York, New York 10032, United
States
- Department of Medicine,
Division of Infectious Diseases, Colombia University, New York, New York 10032, United States
| | - Mark
E. Fitzgerald
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Michael Foley
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Rajarshi Guha
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Paul Hinkson
- Genzyme Corporation, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Martin Kramer
- Genzyme Corporation, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Amanda K. Lukens
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Harvard School of Public Health, Huntington Avenue,
Boston, Massachusetts 02115, United States
| | - Daniela Masi
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Lisa
A. Marcaurelle
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Xin-Zhuan Su
- National Institute of Allergy and Infectious
Diseases, Bethesda, Maryland 20892, United States
| | - Craig J. Thomas
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Michel Weïwer
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Roger C. Wiegand
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Harvard School of Public Health, Huntington Avenue,
Boston, Massachusetts 02115, United States
| | - Dyann Wirth
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Harvard School of Public Health, Huntington Avenue,
Boston, Massachusetts 02115, United States
| | - Menghang Xia
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Jing Yuan
- National Institute of Allergy and Infectious
Diseases, Bethesda, Maryland 20892, United States
| | - Jinghua Zhao
- Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892,
United States
| | - Michelle Palmer
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Benito Munoz
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
| | - Stuart Schreiber
- The Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, United States
- Howard Hughes Medical Institute,
Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| |
Collapse
|
11
|
Masuko S, Bera S, Green DE, Weïwer M, Liu J, DeAngelis PL, Linhardt RJ. Chemoenzymatic synthesis of uridine diphosphate-GlcNAc and uridine diphosphate-GalNAc analogs for the preparation of unnatural glycosaminoglycans. J Org Chem 2012; 77:1449-56. [PMID: 22239739 DOI: 10.1021/jo202322k] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Eight N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-phosphate analogs have been synthesized chemically and were tested for their recognition by the GlmU uridyltransferase enzyme. Among these, only substrates that have an amide linkage to the C-2 nitrogen were transferred by GlmU to afford their corresponding uridine diphosphate(UDP)-sugar nucleotides. Resin-immobilized GlmU showed comparable activity to nonimmobilized GlmU and provides a more facile final step in the synthesis of an unnatural UDP-donor. The synthesized unnatural UDP-donors were tested for their activity as substrates for glycosyltransferases in the preparation of unnatural glycosaminoglycans in vitro. A subset of these analogs was useful as donors, increasing the synthetic repertoire for these medically important polysaccharides.
Collapse
Affiliation(s)
- Sayaka Masuko
- Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Kemp MM, Weïwer M, Koehler AN. Unbiased binding assays for discovering small-molecule probes and drugs. Bioorg Med Chem 2011; 20:1979-89. [PMID: 22230199 DOI: 10.1016/j.bmc.2011.11.071] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Revised: 11/22/2011] [Accepted: 11/30/2011] [Indexed: 11/28/2022]
Abstract
2011 marks the 10-year anniversary of milestone manuscripts describing drafts of the human genome sequence. Over the past decade, a number of new proteins have been linked to disease-many of which fall into classes that have been historically considered challenging from the perspective of drug discovery. Several of these newly associated proteins lack structural information or strong annotation with regard to function, making development of conventional in vitro functional assays difficult. A recent resurgence in the popularity of simple small molecule binding assays has led to new approaches that do not require knowledge of protein structure or function in advance. Here we briefly review selected methods for executing binding assays that have been used successfully to discover small-molecule probes or drug candidates.
Collapse
Affiliation(s)
- Melissa M Kemp
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | | | | |
Collapse
|
13
|
Weïwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S, Palmer M, Stockwell BR, Schreiber SL, Munoz B. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett 2011; 22:1822-6. [PMID: 22297109 DOI: 10.1016/j.bmcl.2011.09.047] [Citation(s) in RCA: 140] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2011] [Revised: 09/12/2011] [Accepted: 09/14/2011] [Indexed: 02/06/2023]
Abstract
Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from the National Institutes of Health-Molecular Libraries Small Molecule Repository (NIH-MLSMR) against immortalized BJ fibroblasts expressing HRAS(G12V) followed by a counterscreen of lethal compounds in a series of isogenic cells lacking the HRAS(G12V) oncogene. This effort led to the identification of two novel molecular probes (PubChem CID 3689413, ML162 and CID 49766530, ML210) with nanomolar potencies and 4-23-fold selectivities, which can potentially be used for identifying oncogene-specific pathways and targets in cancer cells.
Collapse
Affiliation(s)
- Michel Weïwer
- The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Kemp MM, Wang Q, Fuller JH, West N, Martinez NM, Morse EM, Weïwer M, Schreiber SL, Bradner JE, Koehler AN. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg Med Chem Lett 2011; 21:4164-9. [PMID: 21696956 DOI: 10.1016/j.bmcl.2011.05.098] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Revised: 05/24/2011] [Accepted: 05/25/2011] [Indexed: 12/01/2022]
Abstract
Histone deacetylases (HDACs) are enzymes involved in many important biological functions. They have been linked to a variety of cancers, psychiatric disorders, and other diseases. Since small molecules can serve as probes to study the relevant biological roles of HDACs, novel scaffolds are necessary to develop more efficient, selective drug candidates. Screening libraries of molecules may yield structurally diverse probes that bind these enzymes and modulate their functions in cells. Here we report a small molecule with a novel hydroxy-pyrimidine scaffold that inhibits multiple HDAC enzymes and modulates acetylation levels in cells. Analogs were synthesized in an effort to evaluate structure-activity relationships.
Collapse
Affiliation(s)
- Melissa M Kemp
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ, Liu J. Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem 2010; 285:34240-9. [PMID: 20729556 DOI: 10.1074/jbc.m110.159152] [Citation(s) in RCA: 126] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Heparan sulfate is a sulfated glycan that exhibits essential physiological functions. Interrogation of the specificity of heparan sulfate-mediated activities demands a library of structurally defined oligosaccharides. Chemical synthesis of large heparan sulfate oligosaccharides remains challenging. We report the synthesis of oligosaccharides with different sulfation patterns and sizes from a disaccharide building block using glycosyltransferases, heparan sulfate C(5)-epimerase, and sulfotransferases. This method offers a generic approach to prepare heparan sulfate oligosaccharides possessing predictable structures.
Collapse
Affiliation(s)
- Renpeng Liu
- Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Coulombel L, Weïwer M, Duñach E. Aluminium Triflate Catalysed Cyclisation of Unsaturated Alcohols: Novel Synthesis of Rose Oxide and Analogues. European J Org Chem 2009. [DOI: 10.1002/ejoc.200900841] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
17
|
Mora-Pale M, Weïwer M, Yu J, Linhardt RJ, Dordick JS. Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorg Med Chem 2009; 17:5146-52. [PMID: 19523836 PMCID: PMC2723721 DOI: 10.1016/j.bmc.2009.05.061] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2009] [Revised: 05/19/2009] [Accepted: 05/22/2009] [Indexed: 02/07/2023]
Abstract
Enzymatic oxidation of apocynin, which may mimic in vivo metabolism, affords a large number of oligomers (apocynin oxidation products, AOP) that inhibit vascular NADPH oxidase. In vitro studies of NADPH oxidase activity were performed to identify active inhibitors, resulting in a trimer hydroxylated quinone (IIIHyQ) that inhibited NADPH oxidase with an IC(50)=31nM. Apocynin itself possessed minimal inhibitory activity. NADPH oxidase is believed to be inhibited through prevention of the interaction between two NADPH oxidase subunits, p47(phox) and p22(phox). To that end, while apocynin was unable to block the interaction of his-tagged p47(phox) with a surface immobilized biotinylated p22(phox) peptide, the IIIHyQ product strongly interfered with this interaction (apparent IC(50)=1.6microM). These results provide evidence that peroxidase-generated AOP, which consist of oligomeric phenols and quinones, inhibit critical interactions that are involved in the assembly and activation of human vascular NADPH oxidase.
Collapse
Affiliation(s)
- Mauricio Mora-Pale
- Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
| | | | | | | | | |
Collapse
|
18
|
Weïwer M, Chen CC, Kemp MM, Linhardt RJ. Synthesis and Biological Evaluation of Non-Hydrolizable 1,2,3-Triazole Linked Sialic Acid Derivatives as Neuraminidase Inhibitors. European J Org Chem 2009; 2009. [PMID: 24223493 DOI: 10.1002/ejoc.200900117] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
α-Sialic acid azide 1 has been used as a substrate for the efficient preparation of 1,2,3-triazole derivatives of sialic acid using the copper-catalyzed azide-alkyne Huisgen cycloaddition ("click chemistry"). Our approach is to generate non-natural N-glycosides of sialic acid that are resistant to neuraminidase catalyzed hydrolysis as opposed to the natural O-glycosides. These N-glycosides would act as neuraminidase inhibitors to prevent the release of new virions. As a preliminary study, a small library of 1,2,3-triazole-linked sialic acid derivatives has been synthesized in 71-89% yield. A disaccharide mimic of sialic acid has also been prepared using the α-sialic acid azide 1 and a C-8 propargyl sialic acid acceptor in 68% yield. A model sialic acid coated dendrimer was also synthesized from a per-propargylated pentaerythritol acceptor. These novel sialic acid derivatives were then evaluated as potential neuraminidase inhibitors using a 96-well plate fluorescence assay; micromolar IC50 values were observed, comparable to the known sialidase inhibitor Neu5Ac2en.
Collapse
Affiliation(s)
- Michel Weïwer
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, 110, 8th Street, Troy, NY 12180 (USA)
| | | | | | | |
Collapse
|
19
|
Weïwer M, Chen CC, Kemp MM, Linhardt RJ. Synthesis and Biological Evaluation of Non-Hydrolyzable 1,2,3-Triazole-Linked Sialic Acid Derivatives as Neuraminidase Inhibitors (Eur. J. Org. Chem. 16/2009). European J Org Chem 2009. [DOI: 10.1002/ejoc.200990041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
20
|
|
21
|
Yu J, Weïwer M, Linhardt RJ, Dordick JS. The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol 2008; 6:204-17. [PMID: 18673160 DOI: 10.2174/157016108784911984] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Oxidative stress has been linked to the origin and progression of cardiovascular diseases. Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase is a multi-component, NADPH-dependent enzyme that generates superoxide anion in the presence of molecular oxygen. The enzyme has been identified and characterized in all 3 vascular wall cell types and represents the major source of reactive oxygen species (ROS) production in the vascular wall. Inhibition of NADPH oxidase activation appears to suppress the sequence of cellular events that leads to a variety of cardiovascular diseases, including atherosclerosis. The naturally occurring methoxyphenol apocynin has been found to inhibit NADPH oxidase upon activation by peroxidases (e.g. soybean peroxidase, myeloperoxidase) or ROS under mild reaction conditions. Upon peroxidase-catalyzed activation, the apocynin oxidation products act to block the assembly and activation of NADPH oxidase. Although the mechanism of inhibition of NADPH oxidase remains largely unknown, apocynin's high effectiveness and low toxicity makes it a promising lead compound in the development of new therapeutic agents for cardiovascular diseases.
Collapse
Affiliation(s)
- Jingjing Yu
- Department of Biology, Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
| | | | | | | |
Collapse
|
22
|
Zhang Z, Weïwer M, Li B, Kemp MM, Daman TH, Linhardt RJ. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 2008; 51:5498-501. [PMID: 18754653 DOI: 10.1021/jm800785t] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Heparin, a widely used anticoagulant, is being rapidly displaced by low-molecular-weight heparins. Recently, certain lots of heparin have been associated with anaphylactoid-type reactions resulting from contamination with oversulfated chondroitin sulfate. This impurity has also contaminated low-molecular-weight heparins obtained by chemical and enzymatic depolymerization of heparin. The sensitivity of oversulfated chondroitin sulfate to five different depolymerization processes similar to ones used in preparing low-molecular-weight heparins is reported.
Collapse
Affiliation(s)
- Zhenqing Zhang
- Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | | | | | | | | | | |
Collapse
|
23
|
Weïwer M, Sherwood T, Green DE, Chen M, DeAngelis PL, Liu J, Linhardt RJ. Synthesis of uridine 5'-diphosphoiduronic acid: a potential substrate for the chemoenzymatic synthesis of heparin. J Org Chem 2008; 73:7631-7. [PMID: 18759479 PMCID: PMC2639712 DOI: 10.1021/jo801409c] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
An improved understanding of the biological activities of heparin requires structurally defined heparin oligosaccharides. The chemoenzymatic synthesis of heparin oligosaccharides relies on glycosyltransferases that use UDP-sugar nucleotides as donors. Uridine 5'-diphosphoiduronic acid (UDP-IdoA) and uridine 5'-diphosphohexenuronic acid (UDP-HexUA) have been synthesized as potential analogues of uridine 5'-diphosphoglucuronic acid (UDP-GlcA) for enzymatic incorporation into heparin oligosaccharides. Non-natural UDP-IdoA and UDP-HexUA were tested as substrates for various glucuronosyltransferases to better understand enzyme specificity.
Collapse
Affiliation(s)
- Michel Weïwer
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180
| | - Trevor Sherwood
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180
| | - Dixy E. Green
- Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., Oklahoma City, Oklahoma
| | - Miao Chen
- University of North Carolina School of Pharmacy, Division of Medicinal Chemistry and Natural Products, CB no. 7360 Beard Hall, Room 309, Chapel Hill, North Carolina 27599-7360
| | - Paul L. DeAngelis
- Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., Oklahoma City, Oklahoma
| | - Jian Liu
- University of North Carolina School of Pharmacy, Division of Medicinal Chemistry and Natural Products, CB no. 7360 Beard Hall, Room 309, Chapel Hill, North Carolina 27599-7360
| | - Robert J. Linhardt
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180
- Department of Chemical and Biological Engineering and Department of Biology, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180
| |
Collapse
|
24
|
Coulombel L, Grau F, Weïwer M, Favier I, Chaminade X, Heumann A, Bayón J, Aguirre P, Duñach E. LewisSuper‐Acid Catalyzed Cyclizations: A New Route to Fragrance Compounds. Chem Biodivers 2008; 5:1070-82. [DOI: 10.1002/cbdv.200890086] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
25
|
Weïwer M, Chaminade X, Bayón JC, Duñach E. Indium Triflate-Catalysed Addition of Thio Compounds to Camphene: A Novel Route to 2,3,3-Trimethyl-2-thiobicyclo[2.2.1]heptane Derivatives. European J Org Chem 2007. [DOI: 10.1002/ejoc.200601112] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
26
|
Park TJ, Weïwer M, Yuan X, Baytas SN, Munoz EM, Murugesan S, Linhardt RJ. Glycosylation in room temperature ionic liquid using unprotected and unactivated donors. Carbohydr Res 2006; 342:614-20. [PMID: 17173880 PMCID: PMC1905819 DOI: 10.1016/j.carres.2006.11.022] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Revised: 08/29/2006] [Accepted: 11/24/2006] [Indexed: 10/23/2022]
Abstract
Glycosylation in room temperature ionic liquid is demonstrated using unprotected and unactivated donors. Modest yields of simple benzyl glycosides and disaccharides of glucose, mannose and N-acetylgalactosamine were obtained in 1-ethyl-3-methylimidazolium benzoate with Amberlite IR-120 (H(+)) resin or p-toluenesulfonic acid as promoters.
Collapse
Affiliation(s)
- Tae-Joon Park
- Department of Chemical and Biological Engineering, Biotechnology 4005, Rensselaer Polytechnic Institute, 110, 8th Street, Troy, NY 12180, USA
| | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Indium(III) trifluoromethanesulfonate was found to be an excellent catalyst for the highly regioselective intra- and intermolecular addition of thiols to non-activated olefins and could be recycled and reused without loss of activity.
Collapse
Affiliation(s)
- Michel Weïwer
- Laboratoire Arômes, Synthèses et Interactions, Université de Nice-Sophia Antipolis, Parc Valrose, 06108 Nice cedex 2, France
| | | | | |
Collapse
|
28
|
|